Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment
Bausch Health is acquiring DURECT primarily for its lead asset, called larsucosterol. This novel therapeutic molecule is an epigenetic modulator that the FDA has granted Breakthrough Therapy Designation for the treatment of alcoholic hepatitis/AH, which is a life-threatening form of alcohol-associated liver disease.
A closeup of pills in a pharmacy, representing the high quality medications of the company.
AH is characterized by severe liver inflammation & necrosis and accounted for ~164,000 hospital admissions in the US in 2021. There are currently no FDA or European Medicines Agency/EMA-approved treatments for the condition. The acquisition of larsucosterol strengthens Bausch Health's commitment to hepatology. Bausch Health plans to use its expertise to advance larsucosterol through a planned Phase 3 program.
Bausch Health Companies Inc. (NYSE:BHC) is a diversified specialty pharmaceutical and medical device company that develops, manufactures, and markets products in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, OTC products, aesthetic medical devices, and eye health.
DURECT Corporation (NASDAQ:DRRX) is a late-stage biopharmaceutical company that develops epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, such as acute organ injury.
While we acknowledge the potential of BHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the .
READ NEXT: and .
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
TD Securities Raises Suncor Energy (SU) PT to C$63 Following Strong Q2 Performance
Suncor Energy Inc. (NYSE:SU) is one of the most undervalued Canadian stocks to buy now. On August 6, TD Securities raised the price target on Suncor to C$63 from C$62, while keeping a Buy rating on the shares. This announcement followed Suncor's Q2 2025 earnings report, when the company generated $2.7 billion in adjusted funds from operations and $1.0 billion in free funds flow. Net earnings for the quarter were $1.134 billion, compared to $1.568 billion in the same period of 2024. The drop came from lower upstream price realizations. A close-up shot of a large pipeline pumping crude oil and pipe valves in a petroleum trust. Suncor achieved a record second-quarter upstream production of 808,000 barrels per day (bbls/d) and a record H1 production of 831,000 bbls/d. Total Oil Sands bitumen production also hit a Q2 record of 860,800 bbls/d. E&P output increased to 59,700 bbls/d, which included increased production from the Hebron and White Rose fields. Downstream, the company achieved a record Q2 refinery throughput of 442,000 bbls/d, with a utilization rate of 95%, and a record H1 throughput of 462,000 bbls/d. Refinery product sales also set a second-quarter record at 600,500 bbls/d. Suncor Energy Inc. (NYSE:SU) is an integrated energy company in Canada, the US, and internationally. It operates through Oil Sands, Exploration & Production, and Refining & Marketing segments. While we acknowledge the potential of SU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
Raymond James Raises Cenovus Energy (CVE) PT to C$30 Amid Q2 Earnings
Cenovus Energy Inc. (NYSE:CVE) is one of the most undervalued Canadian stocks to buy now. On August 1, Raymond James raised the firm's price target on Cenovus Energy to C$30 from C$29, while keeping an Outperform rating on the shares. This sentiment followed the company's Q2 2025 earnings announcement, where the company reported a total of ~$2.4 billion in cash from operating activities, $1.5 billion in adjusted funds flow, and $355 million in free funds flow. Total revenues for the quarter were $12.3 billion, which was a sequential decrease from $13.3 billion. Upstream production was 765,900 barrels of oil equivalent per day (BOE/d), which showed planned maintenance at the Foster Creek and Sunrise oil sands assets, as well as impacts from a wildfire at Christina Lake. Downstream crude throughput was 665,800 barrels per day (bbls/d), with a utilization rate of 92%, including the early completion of a turnaround at the Toledo Refinery. Oil platform First oil was achieved at Narrows Lake in mid-July in this quarter as well, with production expected to ramp up to a peak of 20,000-30,000 bbls/d by the end of the year. The West White Rose project made progress, with the concrete gravity structure installed on the seabed in June and the topsides placed in mid-July. Drilling is expected to begin by the end of the year, with first oil projected for Q2 2026. At the Foster Creek optimization project, 4 new boilers were brought online in July, adding ~80,000 bbls/d of steam capacity. Cenovus Energy Inc. (NYSE:CVE) develops, produces, refines, transports, and markets crude oil, natural gas, and refined petroleum products in Canada, the US, and China. It operates through Oil Sands, Conventional, Offshore, Canadian Refining, and US Refining segments. While we acknowledge the potential of CVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
B2Gold (BTG) Receives Approval for Underground Mining at Fekola Mine in Mali
B2Gold Corp. (NYSE:BTG) is one of the best Canadian gold stocks to buy according to hedge funds. On July 30, the company announced that Mali's government had granted it approval to commence underground mining at the Fekola Mine. The decision followed meetings between B2Gold executives and senior Malian government officials earlier in July, which the company termed 'productive'. Pushish Images/ B2Gold has already developed more than 9,300 meters of underground workings and installed all necessary mining infrastructure at the site in anticipation of approval. Following the green light, the company has commenced stope ore production, and previously stockpiled underground ore is now being processed through the Fekola mill. The Fekola Complex comprises the Fekola Mine (Medinandi permit), which includes the Fekola and Cardinal open pits, and the Fekola underground mine. B2Gold owns 80% of the mine, while the State holds the rest. The other element of the Fekola Complex is the Fekola Regional (Anaconda Area/Menankoto permit and Dandoko permit), 65% owned by B2Gold and 35% by the State. The company expects Fekola underground to contribute up to 35,000 ounces of gold production in 2025, with further ramp-up in 2026 and subsequent years. Additionally, B2Gold reaffirmed its full-year 2025 gold production guidance for the entire Fekola Complex at 515,000–550,000 ounces. B2Gold Corp. (NYSE:BTG) is a Canadian gold mining company. It acquires, develops, and operates gold properties, primarily through the Fekola mine in Mali, the Masbate mine in the Philippines, and the Otjikoto mine in Namibia. Its main product is gold bullion, produced from open-pit mining operations across its global portfolio. While we acknowledge the potential of BTG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Top 10 Medical AI Companies to Buy According to Analysts. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
